In Reply We thank McCaw et al for their interest in our article.1 They commented that it would be useful to combine efficacy and safety at the individual level through a composite end point. They also suggested that intermediary categories can be constructed to quantify degrees of partial response, which can create a descriptive categorical composite end point. From this approach, the result can be changed favoring intermittent pneumatic compression (IPC) group with an event difference rate of 4.9%. We are very interested in this idea.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Jung YJ, Song KY. Quantifying the Added Value of Low-Molecular-Weight Heparin to Intermittent Pneumatic Compression for Preventing Venous Thromboembolic Events Under the Risk-Benefit Perspective—Reply. JAMA Surg. 2019;154(3):271–272. doi:10.1001/jamasurg.2018.4306
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: